Form 4: Corcept Therapeutics Director Sells Shares

Corcept Therapeutics Director David L. Mahoney reported a sale of 20,000 shares of common stock on June 17, 2026, for an aggregate price of $1,690,500.

Summary

• David L. Mahoney, a Director at Corcept Therapeutics Inc., sold 20,000 shares of common stock on June 17, 2026.
• The sale was executed at a weighted average price of $84.525 per share, with actual sale prices ranging from $84.44 to $85.11.
• The total value of the transaction was approximately $1,690,500.
• Following the transaction, Mahoney beneficially owns 1,237,145 shares indirectly through The Black Dog Private Foundation and the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the director's sale of a substantial number of shares, which may raise questions among investors, though it is a standard disclosure.

Negatives

• Director David L. Mahoney sold a significant number of shares (20,000) which could be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling, particularly by directors, can sometimes signal a lack of confidence in future stock performance, although it can also be for personal financial planning reasons.

Stakeholder Impact

• Shareholders may view the director's sale as a potential negative signal, possibly leading to short-term price pressure.

Key Dates

Recommendation

The filing reports a standard insider transaction (sale of shares by a director) which, while potentially causing minor short-term sentiment shifts, does not provide enough information to warrant a strong buy or sell recommendation. It is prudent to hold and monitor further company developments.

Keywords

Corcept Therapeutics, Form 4, Insider Trading, Stock Sale, Director Transaction, Beneficial Ownership